MTBVAC from discovery to clinical trials in tuberculosis-endemic countries by Marinova, Dessislava et al.
REVIEW
MTBVAC from discovery to clinical trials in tuberculosis-endemic countries
Dessislava Marinovaa,b, Jesus Gonzalo-Asensioa,b,c, Nacho Aguiloa,b and Carlos Martina,b,c
aGrupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Universidad de Zaragoza, Zaragoza, Spain;
bCIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; cServicio de Microbiología, Hospital Universitario Miguel Servet,
ISS Aragón, Zaragoza, Spain
ABSTRACT
Introduction: BCG remains the only vaccine against tuberculosis (TB) in use today and despite its
impressive global coverage, the nature of BCG protection against the pulmonary forms of TB remains
subject to ongoing debate. Because of the limitations of BCG, novel TB vaccine candidates have been
developed and several have reached the clinical pipeline. One of these candidates is MTBVAC, the first
and only TB vaccine in the clinical pipeline to date based on live-attenuated Mycobacterium tubercu-
losis that has successfully entered clinical evaluation, a historic milestone in human vaccinology.
Areas covered: This review describes development of MTBVAC from discovery to clinical development
in high burden TB-endemic countries. The preclinical experiments where MTBVAC has shown to confer
improved safety and efficacy over BCG are presented and the clinical development plans for MTBVAC
are revealed. The search of all supportive literature in this manuscript was carried out via Pubmed.
Expert commentary: Small experimental medicine trials in humans and preclinical efficacy studies with
a strong immunological component mimicking clinical trial design are considered essential by the
scientific community to help identify reliable vaccine-specific correlates of protection in order to
support and accelerate community-wide efficacy trials of new TB vaccines.
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1. Introduction
Bacille Calmette–Guérin (BCG) vaccine is an attenuated strain
of Mycobacterium bovis, the etiologic agent of tuberculosis
(TB) in cattle [1]. BCG was introduced for the first time into
clinical use almost a hundred years ago, when in 1921 it was
given orally to an infant whose mother had died of TB a day
after delivery. The infant showed no adverse events to vacci-
nation with BCG and importantly, did not develop TB. At that
time, the oral route of BCG administration was considered the
natural (gastrointestinal tract) route for acquiring TB in infants
and children fed with unpasteurized milk [2].
TB is poverty related with major burden in the poor and
developing parts of the world. The incidence of TB is increas-
ing worldwide due to poverty and inequity and is aggravated
with the HIV/AIDS pandemic, which greatly increases risk of
infection proceeding to active disease [3]. Diabetes, metabolic
syndrome, smoking and more recently vitamin deficiencies
due to malnutrition and poor socioeconomic conditions are
emerging as important risk factors for TB [4,5]. Importantly,
how these factors can influence efficacy evaluation of new TB
vaccines requires specific attention when defining clinical trial
designs that involve study or patient populations with a vari-
ety of such risk factors. Because of the rising globalization and
emergence of multidrug-resistant (MDR) and extensively drug-
resistant TB (XDR) strains, TB is increasingly becoming a ser-
ious threat for the entire world. Today TB has reached alarm-
ing proportions of 10.4 million incidence cases and 1.8 million
deaths attributed to the disease as reported by the latest
World Health Organization (WHO) global TB report 2016 [4].
Globally, some 50 million individuals are already latently
infected with MDR M. tuberculosis strains creating a remark-
able resource for future cases of active TB with insufficient
treatment options [3]. Nevertheless, the WHO End TB Strategy
has vowed to reduce TB morbidity by 90% and TB mortality by
95% by 2035 and recognizes the urgent need for more acces-
sible diagnostic tools that are rapid and reliable, new less toxic
and more efficacious antibiotics to shorten therapy and ulti-
mately new vaccines to prevent pulmonary TB in order to
achieve this ambitious goal [4].
2. Search strategies
The search of all supportive literature was carried out via the
PubMed service of the US National Library of Medicine and
key articles, which we considered representative of the topics
reviewed, including BCG history, current state-of-the-art in the
field of TB vaccine research and development, were selected.
3. BCG
3.1. The debatable efficacy of BCG
BCG remains the only licensed vaccine against TB. It is inex-
pensive and requires only one contact with health services at
birth. Despite its impressive global coverage, the nature of
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BCG protection and the risks of BCG vaccination in HIV-
infected children remain subject to ongoing debate [6,7]. In
infants, BCG is acknowledged to afford protection against
disseminated (miliary and meningeal) forms of TB [8,9],
whereas in adolescents and adults BCG vaccinated at birth,
lack of BCG efficacy against respiratory (pulmonary) TB disease
is considered to be a result of waning BCG immunity with time
that is gradually lost 10 years after vaccination [10]. In high-
burden TB-endemic developing countries, newborns are
highly susceptible to infection with M. tuberculosis for which
they receive BCG immediately after birth to ensure TB preven-
tion [11]. However, emerging epidemiological data show that
BCG protection against miliary TB and TB meningitis is not
absolute. In the Western Cape Province of South Africa, where
BCG coverage approaches 95%, TB meningitis is currently the
most common cause of childhood bacterial meningitis [12].
Earlier studies in the same region show that more than 80% of
children with TB meningitis had received BCG [13,14].
Moreover, the recent infant efficacy trial with the subunit
candidate MVA85A conducted in the Western Cape Province
of South Africa, revealed an alarming TB incidence rate of
~1.5% in infants who had been recently vaccinated with BCG
at birth [15], and, what is more, this incidence is twice that of
adolescents or young adults in the same geographical area,
the age group where BCG-induced immunity at birth is con-
sidered to have no effect [11]. Although final conclusions
cannot be drawn from a single study, these data raise serious
concerns as to whether BCG is really effective in preventing TB
even in newborn infants.
There are many and varied hypotheses as to why there is
such variation in BCG efficacy; however, none has given the
definite answer. It is thought that over-attenuation of BCG due
to loss of important immunodominant antigens (e.g. those in the
region of difference 1 (RD1) region) in the process of its attenua-
tion by repeated subcultivation passaging in nonstandardized
conditions could be one of the reasons [16,17]. Moreover, large
number of human clinical trials suggest that revaccination with
BCG does not provide additional benefit, which could be due to
preexisting heterologous immunity resulting from infection with
nontuberculous environmental mycobacteria (NTM), a process
known as masking and blocking [18,19].
Although BCG efficacy against TB is debatable, its safety in
healthy infants is unquestionable, as no clinical trial to date has
shown BCG to have important harmful effects. However, BCG
remains one of most reactogenic (local skin reaction) vaccines
known today [20,21], which possibly explains in part why it has
been removed from the vaccination calendar in low-burden
developed countries [4]. Given the limitations of BCG and the
WHO declaration in 1993 of TB as a global health emergency, the
past 20 years have seen an intensive upsurge in the research and
discovery of new TB vaccine candidates. Mainly European driven,
the work has been highly fostered by the European Commission
Framework Funding Programs resulting in many of these candi-
dates to reach current clinical development.
3.2. Nonspecific benefits of BCG vaccination at birth
An increasing number of observational studies have provided
evidence that live BCG may reduce child morbidity and
mortality in ways other than TB prevention [22]. For example,
trials from West Africa revealed that BCG reduces neonatal
mortality by more than 40%, mainly by preventing neonatal
sepsis and respiratory infections and fever [23]. Another small
study in low-birth-weight children conducted in the USA and
the UK deduced that administration of BCG vaccine at first
contact might contribute to lower mortality [24,25]. Moreover,
neonatal BCG vaccination in clinic has been shown to induce a
strong TH1-cell-polarizing cytokine response that can enhance
immune responses to other neonatal vaccines [26]. Recently,
protection of neonatal BCG vaccination against hospitalization
due to respiratory infection and sepsis in low TB endemic
countries has been described [27]. Kleinnijenhuis et al. recently
provided evidence that BCG may induce nonspecific resistance
(T- and B-cell dependent) to pathogens via epigenetic repro-
gramming of monocytes [28]. Moreover, these effects are
shown to be mediated by the functional and epigenetic repro-
gramming of innate immune cells such as monocytes, macro-
phages, and NK (natural killer) cells, a process termed ‘trained
immunity’ [29,30]. And most recently, Arts et al. [31], showed
essential roles for metabolic pathways in BCG induced trained
immunity in human monocytes. Moreover, induction of these
pathways is regulated by epigenetic mechanisms at the level
of chromatin organization, calling for future studies on the
potential therapeutic role that the modulation of these path-
ways may have during vaccination [31]. Finally, most European
countries where incidence of TB is now low, have relinquished
BCG from their vaccination schedule or restricted it to high-
risk groups; however, subsequent studies suggest that this
policy may have increased the incidence of a wide variety of
conditions, including atopic dermatitis [12].
Considering that BCG is consistently used as the reference
gold standard comparator in preclinical and clinical evaluation
of new TB vaccines (e.g. it has a well-established safety profile)
[32,33], it is important to consider the nonspecific immunity
attributed to BCG as potential benefit to be incorporated into
the development of new TB vaccines, especially those
designed as BCG-replacement strategies.
4. The current clinical TB vaccine pipeline
Today, there are a total of 13 candidates in the current clinical
TB vaccine pipeline and they can be classified into three
groups [2]. One encompasses preventive pre-exposure vac-
cines, aimed for administration prior to first exposure to M.
tuberculosis. They can target either BCG-naive newborns,
hence priming BCG-replacement strategies, or to boost immu-
nity to BCG-induced immune responses in healthy infants,
adolescents and adults vaccinated at birth, hence subunit
BCG boosters. The second category includes the preventive
post-exposure vaccines, which primarily comprise subunit vac-
cines that target individuals who have latent TB infection
(LTBI) with the aim to reduce the risk of progression to active
TB in those who do not receive treatment. The third class of
vaccine candidates are aimed as immune-therapeutic strate-
gies in conjunction with antibiotic therapy for active TB. These
candidates consist normally of fractioned or killed whole cell
mycobacteria pertaining to the M. tuberculosis complex
(MTBC) or to other distal mycobacterial species. The most
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recent detailed revision of these candidates and where they
are to date can be found in Kaufmann et al., 2016 [2], the WHO
Report 2016 [3], or 2016 TAG Report on TB Prevention by Mike
Frick [34], among others.
Although, prevention of infection (primary or secondary) or
sterilizing protection would be the optimum target for any of
the preventive class of vaccines, most TB vaccines in the
clinical and preclinical portfolios today are intended for pre-
vention of disease. Concerning subunit vaccines, they are
based on one or more immunodominant antigens specific to
BCG and to early and or late phase M. tuberculosis infection,
using live viral vectors or adjuvants as delivery systems [2]. In
general, these subunit candidates are intended to enhance
preexisting immune responses to certain immunodominant
antigens induced upon BCG vaccination at birth and or upon
M. tuberculosis infection in BCG vaccinated individuals (infants,
e.g. MVA85A vaccine trial in adolescents and adults) [35–37].
In the design of new BCG-replacement strategies, it is impor-
tant to consider the well-acknowledged BCG efficacy against
extrapulmonary TB in children [8,9], making it highly desirable
that such potential new candidates include this characteristic of
BCG. The current pipeline has only two candidates aiming to
replace BCG and they are based on live-attenuated mycobac-
teria. The most advanced candidate in clinical development
today is the recombinant BCG (rBCG) VPM1002 which is now
in efficacy trials aimed to prevent TB in infants with and without
HIV exposure [12]. The other candidate is the live-attenuated M.
tuberculosis MTBVAC, which is the first vaccine of its kind to
successfully enter human clinical evaluation in the history of
human vaccinology. These two candidates could eventually
replace BCG, if able to demonstrate improved safety and or
greater efficacy than BCG when administered in newborns in
high-burden TB-endemic settings.
The main advantage of using rationally attenuated live M.
tuberculosis as vaccine is that many genetic regions encoding
important immunodominant antigens absent in BCG are still
present in attenuated M. tuberculosis, while chromosomal
deletions in virulence genes provide assurance for safety and
genetic stability. These vaccines are expected to safely induce
more specific and longer-lasting immune responses in humans
that can provide protection against TB [38]. This is the ratio-
nale that has been followed in the development of the live-
attenuated MTBVAC.
5. MTBVAC: the unfolding story of the development
of the first live-attenuated M. tuberculosis vaccine
MTBVAC was constructed by rational attenuation of the clin-
ical isolate M. tuberculosis Mt103 [39]. This isolate belongs to
the modern M. tuberculosis Lineage 4, which together with
Lineage 2 (Beijing strains), represents the most geographically
widespread lineages of MTBC transmitted by the aerosol route
between humans [40]. The primary reasons for using a clinical
strain for MTBVAC design and construction were to achieve a
representative antigen repertoire of the clinical M. tuberculosis
strains transmitted between humans and at the same time to
avoid the inherent effects that come with laboratory strains
(such as H37Rv) as result of repeated sub-cultivation in vitro
[41–44], the same process that lead to BCG attenuation
(between 1908 and 1921) and strain diversity afterwards [1].
For example, a single-nucleotide insertion in the whiB6 pro-
moter in M. tuberculosis H37Rv has shifted the role of PhoP
from transcriptional activator to transcriptional repressor,
resulting in lower levels of ESAT-6 expression and secretion
in H37Rv [43]. This polymorphism was shown to be absent in
any of the other publicly available MTBC genomes or in 76
clinical M. tuberculosis isolates (including MTBVAC parental
strain Mt103) analyzed [43].
6. MTBVAC
6.1. MTBVAC and BCG: phylogenetic similarities and
differences
MTBVAC and BCG are both live-attenuated derivatives of the
TB pathogens in humans (M. tuberculosis) and in cattle (M.
bovis), respectively (Figure 1). Both M. tuberculosis and M.
bovis are related members of the MTBC, which are character-
ized by more than 99.95% similarity at the nucleotide level,
identical 16S rRNA sequences and a strictly clonal population
structure without ‘recent’ evidence of ongoing horizontal
gene transfer between them [45]. Both M. tuberculosis and M.
bovis emerged after an evolutionary bottleneck from a most
recent common ancestor (MRCA) [46]. Today, global genome
sequencing analyses have shown that M. bovis has smaller
chromosomal content relative to the human-adapted patho-
gen M. tuberculosis, due to numerous genomic deletion
events. Specifically, the absence of region of difference 9
(RD9) and other specific RD regions allows branching M.
bovis from M. tuberculosis [46] (Figure 1).
During the in vitro process of BCG attenuation between
1908 and 1921, more than 100 genes were lost from BCG
relative to M. tuberculosis [1]. Among them, deletion of the
RD1 region, which encodes the protein secretion system ESX-
1, is considered the most relevant deletion responsible for BCG
attenuation [1]. It is generally well assumed that T cell epi-
topes are evolutionarily conserved in the MTBC [48,49]. Copin
et al. [50] compared the sequence diversity of 1530 experi-
mentally verified human T cell epitopes and found that 23% of
the known MTBC T cell epitopes are absent in BCG. The
majority (82%) of these absent epitopes are contained in 6
antigenic proteins encoded in RD1 and RD2 deleted in BCG
strains. These and related studies further suggested that epi-
tope sequence variation in BCG potentially affects human T
cell recognition that could result in ineffective priming of the
host immune system [16,17,50–52].
6.2. MTBVAC vaccine construction
MTBVAC is a live vaccine based on genetically attenuated M.
tuberculosis of the clinical isolate Mt103 [39,53]. MTBVAC
attenuation is based on two independent stable genetic dele-
tions, without antibiotic resistance markers, in the genes phoP
and fadD26 encoding two major virulence factors [39]. The
gene phoP encodes the transcription factor of the two-com-
ponent virulence system PhoPR and the gene fadD26 is one of
the 13 genes responsible for biosynthesis and export of
phthiocerol dimycocerosates (PDIM), the main virulence-
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associated cell-wall lipids of M. tuberculosis [54–56]. PhoP has
been shown to regulate more than 2% of M. tuberculosis
genome, most of which implicated in virulence [57,58], and
this regulation could be mediated through other transcription
factors, for example, Whib6 of the ESX-1 system [43] or via
noncoding RNAs (ncRNAs), such as the recently described
mcr7 and its role in activating the TAT secretion system in
MTBVAC leading to over secretion of major antigens such as
the Ag85 complex [59]. Other relevant virulence genes regu-
lated by PhoP include lipid metabolism genes (e.g. pks2, pks3)
involved in biosynthesis of the polyketide-derived acyltreha-
loses (DAT, PAT) and sulfolipids (SL), which are front-line lipid
constituents of the cell wall thought to have a role in host
immune modulation upon first contact of M. tuberculosis with
the human host cells [41,60]. PhoP also regulates genes within
ESX-1 (e.g. the espACD locus) implicated in the secretion of the
major antigen and virulence factor ESAT-6, so that phoP
mutants can produce but are unable to export ESAT-6 [61].
6.3. MTBVAC characterization process
MTBVAC was constructed to contain two independent non-
reverting deletion mutations, without antibiotic markers, ful-
filling the first Geneva consensus safety requirements for
advancing live mycobacterial vaccines to phase I clinical eva-
luation [33]. MTBVAC was genetically engineered to phenoty-
pically and functionally resemble its prototype SO2. SO2 is a
marked Mt103 phoP mutant by the insertion of a kanamycin
resistance cassette (kmr) (Mt103phoP::kmr) [62], which in addi-
tion to the engineered PhoP-deficient phenotype, SO2 has an
acquired spontaneous loss in PDIM biosynthesis [53]
(Figure 2), a process described to be common in M. tubercu-
losis as result of repeated laboratory subculture and manipula-
tion practices [55,63]. In MTBVAC, the introduction of an
unmarked deletion in fadD26 ensures a genetically stable
abolishment of PDIM biosynthesis [39]. SO2 has a thorough
and complete preclinical history demonstrating robust safety
and attenuation profile and promising efficacy compared to
BCG in relevant animal models [64–68]. Most of these precli-
nical studies have been reproduced with MTBVAC to confirm
functional profile and biological activity of the double attenu-
ating PhoP-/PDIM-deficient phenotype. Lipid profile analyses
have demonstrated that MTBVAC and its prototype SO2 are
phenotypically comparable lacking DAT, PAT, and PDIM [39].
To progress to first-in-human phase I clinical evaluation,
MTBVAC was developed and characterized as a freeze-dried
vaccine product by the Spanish Biopharmaceutical company,
Biofabri, in compliance with current Good Manufacturing
Practices (cGMP), fulfilling regulatory guidelines for assuring
the quality, safety and stability, and efficacy of BCG freeze-
dried vaccine [39]. A summary of the preclinical development
of MTBVAC is presented in continuation placing special
emphasis on those studies where improved efficacy and safety
relative to BCG were observed.
7. Preclinical characterization of MTBVAC
7.1. Safety and attenuation profile of MTBVAC and its
prototype SO2 relative to BCG
Any novel live TB vaccine candidate must demonstrate com-
parable or better safety and attenuation profile than BCG in
recognized preclinical animal models as a safety requirement
for entry into first-in-human clinical evaluation [32,33]. The
most recognized animal models for evaluation of safety
attenuation of new TB vaccine candidates to date include
the extremely TB susceptible immunocompromised SCID
mice, which lack adaptive immune responses (T and B cells)
important for containing TB infection, and guinea pigs, which
can develop disease after infection with very few bacilli <5
Figure 1. Phylogenetic tree of the M. tuberculosis complex and depiction of M. tuberculosis, BCG and MTBVAC. The tree depicts the regions of difference (RDs)
deleted between M. tuberculosis and M. bovis in the process of evolution with their host. BCG has lost additional RDs that have led to attenuation. The number of
epitopes of some RD regions is also indicated. MTBVAC is represented to have the antigenic repertoire of M. tuberculosis absent in BCG, expected to confer
protection against disease similar to latent M. tuberculosis infection in humans [47], and at the same time presenting attenuation profile that is comparable to BCG.
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[69]. In these models, vaccine safety is commonly measured in
terms of survival kinetics, viable vaccine bacteria in lung and
spleen and signs of disease (pathology) at necropsy.
Robust safety attenuation profile of the doubly attenuated
PhoP-/PDIM-deficient prototype SO2 was demonstrated in two
SCID mouse models published in Martin et al., 2006 [66]. One
study showed that by the aerosol route SO2 is unable to cause
disease or adverse events, and mice survived >245 days, when
experiment was ended. The other study showed that by intra-
venous (IV) route, SO2 inoculation renders greater survival to
SCID mice than BCG Pasteur [66]. The remaining safety studies
were designed in agreement with regulatory and Geneva
consensus guidelines exclusively for the characterization of
the final vaccine product MTBVAC in mice (SCID and BALB/c)
and guinea pigs [39]. Designs mainly followed administration
by the subcutaneous (SC) route (the accepted route mimicking
clinical intradermal administration of BCG) and a dose equiva-
lent to 50 standard human doses of BCG, approx. 2.5×107 CFU.
By this route and dose of administration, all data showed
comparable safety and attenuation profile for MTBVAC (and
SO2) and BCG SSI, which is the strain used as control com-
parator in MTBVAC phase I clinical evaluation in adults [70]
and in newborns (NCT02013245). Additionally, biodistribution
and formal toxicity studies showed that intradermal inocula-
tion of MTBVAC presents lack of toxicity, limited organ biodis-
tribution and persistence, and untraceable excretion in urine
and stool up to six months post vaccination, comparable to
BCG SSI, as well as appears to be less reactogenic than BCG in
mice and guinea pigs [39]. Finally, in newborn mice MTBVAC
and BCG SSI presented a comparable safety and lack of toxi-
city profile, as measured by health appearance, normal growth
and development behavior, survived until fixed end point
(6 months), and there were no effects on organ development
at necropsy [71].
In the context of vaccine safety, horizontal transmission of
genetic material is a topic of increasing interest in relationship to
TB. In this regard, it should be considered that like BCG, MTBVAC is
a rational derivative of the related members of MTBC, character-
ized by more than 99.95% similarity at the nucleotide level, iden-
tical 16S rRNA sequences and a strictly clonal population structure
[45]. To our knowledge, with the exception ofM. canettii (themore
closely related MTBC ancestor), there has been no evidence of
horizontal gene transfer between members of the MTBC [72]. This
provides strong bases to consider that the probabilities of hor-
izontal gene transfer events and reversion to virulence of MTBVAC
and BCG are highly unlikely. Supporting this hypothesis, it should
be considered that over the long history of BCG use in humans,
which is nowmore than 96 years of global vaccination coverage in
more than 3 billion individuals worldwide (>100,000,000 new-
borns vaccinated per year), to our knowledge of the existing
literature, there have been no reported adverse events due to
reversion to partial or full virulence of BCG as result of horizontal
gene transfer eventswith other related or unrelatedmycobacterial
species of the MTBC. In addition, preclinical studies with MTBVAC
and its prototype SO2, have confirmed lack of horizontal gene
transfer upon infection with wild-type M. tuberculosis in MTBVAC
or SO2 vaccinated animals.
7.2. Protective efficacy and immunogenicity of MTBVAC
and prototype SO2 relative to BCG
Protective efficacy in preclinical animal models, together with
safety and immunogenicity in phase I and phase IIa clinical trials,
are the threemain gate criteria used to select themost promising
candidates to progress to phase IIb/III efficacy testing [73].
Since 2001, rigorous preclinical efficacy and immunogenicity
studies of prototype SO2 and final vaccine construct MTBVAC
were conducted in recognized animal models, including immu-
nocompetent BALB/c or C57BL/6 mice and guinea pigs, and
nonhuman primates [33,74], by independent (national and
international) laboratories. As for all TB vaccine candidates to
date, the protective efficacy of MTBVAC and SO2 was measured
in terms of improvement of bacterial load (expressed as colony
forming units or CFU) in lungs and spleen at a fixed time point
Figure 2. MTBVAC and SO2 genetic and phenotypic profile. Figure depicts the marked phoP mutation by insertion of a Kanamycin resistance cassette (Kmr) insertion
and spontaneous loss in the virulence-associated phthiocerol dimycocersate (PDIM) lipids in SO2 and the stable unmarked genetic deletions in phoP and fadD26 in
MTBVAC. Since MTBVAC was constructed using the SO2 background, MTBVAC also has the spontaneous loss in PDIM present in SO2 and deletion in fadD26 ensuring
a genetically stable PDIM deficient phenotype.
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post challenge, body weight gain, reduced lung pathology
score, and when possible, long-term survival relative to gold
standard BCG [73]. In the recognized small animal models (mice
and guinea pigs), BCG is considered to confer a relatively good
protection against M. tuberculosis challenge, as measured by
1–3 log reduction in CFU counts (variable between models), or
a significant degree of improvement in survival or pathology
score [69,73–76]. With this consideration, the minimum accep-
table efficacy criteria set by the Geneva Consensus require-
ments for advancing new TB vaccines to clinical development
include a significant higher reduction in lung bacterial burden
of >0.5 logs CFU in comparison to BCG [32,33], which was
followed in the MTBVAC preclinical development program.
Regarding evaluation of vaccine-induced immunogenicity, var-
ious parameters can be measured in mice, nonhuman primates
(NHP) and humans, however, in the face of the current lack of
immune correlates of protection against TB, the immunogeni-
city readouts to date have predominantly allowed to deduce
vaccine take.
Considering the limitations of the current animal models,
there has not been an experiment to date (published or unpub-
lished) where protective efficacy, immunogenicity or safety of
MTBVAC (and SO2) has not been comparable or superior to
standard BCG vaccination. Most MTBVAC and SO2 protection
and immunogenicity studies (which follow standard design of
low-dose challenge and efficacy evaluation at short term (8–
12 weeks) post challenge) have shown comparability to gold
standard BCG. However, there are few exceptions where superior
efficacy and immunogenicity were observed, and these studies
varied in using high challenge dose and evaluation of long-term
efficacy, including survival. One of these exceptional studies was
the high-dose challenge long-term survival experiment in guinea
pigs conducted at Public Health England (PHE), where MTBVAC
prototype SO2 conferred 100% survival (6/6 guinea pigs) relative
to 33% survival in the BCG SSI group (2/6 guinea pigs), as well as
significantly greater reduction in severity of disease and bacterial
burden in lungs and spleen [66,75]. Improved protective efficacy
of SO2 relative to BCG SSI was also observed in the nonhuman
primate rhesusmacaquemodel at the National Primate Research
Centre, where, despite ability of both vaccines to confer efficacy
compared to unvaccinated controls (e.g. by increase in total
body weight, significantly reduced gross lung lesions, wasting
and systematic inflammation), SO2 showed an average of reduc-
tion in lung bacillary load of 1.2 log CFU as compared to 0.43 log
CFU conferred by BCG relative to the unvaccinated control group
[68]. Moreover, SO2 but not BCG vaccination revealed significant
body weight gain andmarked reduction in lung pathology when
compared to unvaccinated controls. Serum C-reactive protein
assessment indicated that vaccination with prototype SO2 or
BCG Danish leads to significant reduction in systemic inflamma-
tory response after challenge when compared to unvaccinated
controls [68]. In adult and newborn C57BL/6 mice MTBVAC con-
fers significantly greater protection than BCG SSI as measured by
significant CFU reduction (>0.5 log) in lung bacterial burden
[39,71]. Of note, in the well-established guinea pig model at
PHE, BCG is given at a lower 5×104 CFU dose, and in those studies
MTBVAC and SO2 administration normally followed the same
vaccination regimen as that of BCG to allow for data comparison.
Importantly, preclinical efficacy data in mice and guinea pigs
have demonstrated that efficacy of BCG and MTBVAC vaccines
is dose independent by the SC route, at least in short-term
protection experiments [39,77].
Some of the most abundant antigenic proteins in M.
tuberculosis described include Ag85B and Ag85A. These anti-
gens are constituents of some of the most clinically
advanced subunit vaccines in the pipeline to date [2,3],
designed to boost BCG-induced immunity at birth mainly
in adolescents and adults [78]. Ag85B was expressed in the
recombinant BCG, rBCG30, demonstrating improved efficacy
in guinea pigs over BCG [79]. This led us to study expression
and immunogenicity of Ag85B in prototype SO2 and
MTBVAC in more detail. In a model of adult C57BL/6 trans-
genic mice expressing a T cell receptor (TCR) specific for a
peptide of Ag85B, immunogenicity studies at University of
Sydney showed that vaccination with SO2 induced a marked
expansion of Ag85B-specific CD4 + T cell responses [67].
These Ag85B-specific T cells presented an increased fre-
quency of persisting at extended time points displaying a
central memory phenotype, a property not shared by BCG.
Moreover, upon M. tuberculosis challenge, SO2 group
showed significantly greater recall of vaccine-induced mem-
ory cells to secondary infection which was of increased
magnitude compared to that of the BCG group [67]. In
newborn C57BL/6 mice, MTBVAC vaccination induced differ-
ential immune response to Ag85B compared to BCG vacci-
nation, as measured by IFNγ secretion in splenocytes [71]. A
plausible explanation for these differential immune
responses to Ag85B between MTBVAC (or SO2) and BCG
could be due to an acquired point mutation in the fbpB
gene in all BCG sub-strains, which results in an unstable
protein [50]. Interestingly, in addition to the rich antigen-
specific repertoire inherent of MTBVAC, recent data by our
group observed that the PhoP-dependent ncRNA mcr7 leads
to an increased activity of the Tat-C secretion system result-
ing in greater secretion of Ag85 complex proteins in
MTBVAC [44,59]. Intriguingly, MTBVAC vaccination in new-
born C57BL/6 mice revealed greater immune response to
stimulation with purified protein derivative (PPD) of secreted
M. tuberculosis antigens, relative to BCG, whereas adult
C57BL/6 mice showed comparable PPD responses for both
vaccine groups [39]. This makes us suspect that in clinical
trials, the immune response induced by MTBVAC vaccination
in naïve newborns could be more robust or distinguished
than that induced by neonatal BCG vaccination.
8. MTBVAC GMP and clinical development
8.1. GMP development of MTBVAC to support entry into
first-in-human clinical trials
The success of the preclinical and GMP development of
MTBVAC to support phase I clinical evaluation is result of the
close collaborative partnership between University of
Zaragoza (Unizar), Biofabri, and the European non-for-profit
TuBerculosis Vaccine Initiative (TBVI) [80]. Moreover, the
MTBVAC project has counted with a robust preclinical, regu-
latory and clinical expertise from the TBVI Product
Development and Clinical Development Teams (TBVI PDT
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and CDT), gratefully acknowledged in [39] and [70]. In Oct
2012, MTBVAC was granted approval to enter a first-in-
human phase Ia clinical trial at Lausanne University Hospital
(CHUV) in Switzerland, led by the Principal Investigator (PI)
Prof. François Spertini. The study primary objective was safety
and local tolerance of MTBVAC in comparison with BCG SSI
with minimum secondary immunogenicity in healthy adult
volunteers without any history of BCG vaccination, or expo-
sure to TB (PPD-negative) and or HIV. Successful completion
demonstrated that vaccination with MTBVAC was at least as
safe as BCG, and did not induce serious adverse events [70].
And although no statistical significance could be achieved due
to the small group size of the trial, the immunogenicity data
showed that MTBVAC was at least as immunogenic as BCG,
and at the same dose level as BCG, MTBVAC group showed
greater frequency of polyfunctional CD4+ central memory T
cells. This first phase I trial marks a historic milestone in human
vaccinology, as for the first time a live-attenuated M. tubercu-
losis vaccine has entered clinical trials showing excellent safety
profile and differential immunogenicity profile compared to
BCG supporting clinical development in high-burden TB ende-
mic countries (Figure 3).
8.2. Clinical development plans of MTBVAC
Today, Biofabri is officially the industrial manufacturer and
exclusive licensee of MTBVAC (also Sponsor of the Clinical
Trials of MTBVAC) and together with its faithful partner and
MTBVAC intellectual owner Unizar they have set two indepen-
dent clinical development plans (CDPs) for MTBVAC under the
umbrella of TBVI. One CDP is also in collaboration with US-
founded nonprofit TB vaccine R&D organization Aeras [81] and
focuses on the development of MTBVAC as a preventive
vaccine in adolescents and adults (BCG-vaccinated at birth)
living in high-burden countries with or without prior infection
with M. tuberculosis (Figure 3). In support of this strategy are
the recently published results of the protection study in the
well-established guinea-pig model of aerosol TB infection at
PHE (UK), comparing BCG and MTBVAC vaccination schedules
in prime-boost combination or alone (Clark et al. JID in press
https://doi.org/10.1093/infdis/jix030). The efficacy data of this
study suggested that MTBVAC immunity is longer lasting than
BCG when given as a single dose and that long and short
intervals between BCG prime and MTBVAC boost resulted in
improved efficacy in lungs compared to BCG alone. Plans to
support a phase IIa dose-defining study (NCT 02933281)
before progressing to a multicenter prevention-of-disease
phase IIb/III trial are underway. The second CDP of MTBVAC
is focused on the development of MTBVAC as a preventive
vaccine for newborns, which could replace BCG if improved
safety and or efficacy is demonstrated (Figure 3). Currently, a
phase Ib trial of MTBVAC in healthy newborns is being con-
ducted by the South African Tuberculosis Vaccine Initiative
(SATVI) in the high-burden TB-endemic region of Worcester,
South Africa, with PI Dr. Michele Tameris (NCT02729571). The
study design is set to evaluate the safety and immunogenicity
of MTBVAC in comparison with BCG SSI in newborns living in a
TB endemic region. As a safety step prior to starting vaccina-
tion of newborns, a safety arm in healthy M. tuberculosis-
unexposed adults was successfully completed in Dec 2015
with no reported vaccine-related adverse events. Newborn
vaccination stage has already ended and final data safety
and immunogenicity reports are expected 2nd quarter 2017.
This newborns phase Ib trial is conducted with the aim to
advance to a phase IIa dose-defining study to allow progress
to community wide efficacy evaluation.
Figure 3. Development of MTBVAC from discovery to clinical development. The figure represents the chronological order of the steps in the discovery of phoP,
construction and characterization of SO2 and MTBVAC, and the GMP, preclinical and clinical development of final product MTBVAC freeze-dried vaccine. Meaning of
abbreviations: CTP – Clinical Trial Protocol; CMC – Chemistry, Manufacturing, and Controls; IB – Investigator’s Brochure; CTP – Clinical Trial Protocol; CTA – Clinical
Trial Application.
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8.3. The Quantiferon TB-diagnostic test and implications
for MTBVAC clinical trials
Being a live-attenuated M. tuberculosis derivative, MTBVAC can
express the M. tuberculosis antigen repertoire, which also
includes the highly immunodominant ESAT-6 and CFP-10 anti-
gens, albeit impaired secretion of ESAT-6 due to the deletion
in phoP. This makes one reason that at some point during
vaccine clearance from the organism, the immune system
could detect these antigens. This calls for significant consid-
erations for the potential implications of the current
Quantiferon assay for in vitro diagnosis of TB infection (based
on ESAT-6, CFP-10 and TB7.7) in MTBVAC clinical trials in TB-
endemic regions. Relevant to this, in the MTBVAC phase Ia trial
in adults in Lausanne, ELISpot conversion data to PPD, and to
separate antigens ESAT-6 and CFP-10 showed responses to
ESAT-6 that stayed below threshold for a positive test readout
of infection with M. tuberculosis, while there was a transient
increase in CFP-10-specific IFNγ response over the limit of
positivity in two of nine subjects from the intermediate
MTBVAC dose group (5×104 CFU) and in one subject of
MTBVAC high-dose group (5x105 CFU) at day 28, which at
day 270 (end of study) was below threshold for M. tuberculosis
infection [70]. These results are supported by recent data in
goats where vaccination with SO2 induced a transient ESAT-6/
CFP-10 positivity in 50% of the animals [82]. Although the
group numbers of the phase Ia are too small to achieve
statistical significance for these data, detailed clinical charac-
terization of MTBVAC-induced responses to these and other
antigens are needed. Most importantly, there may be a need
for adapting the current Quantiferon/ELISpot TB diagnostic
tests to reliably distinguish between MTBVAC vaccination
and M. tuberculosis infection in clinical trials.
Relevant to these observations, recent studies have shown
that most of the experimentally confirmed human T cell epi-
topes of M. tuberculosis are concentrated in ESAT-6 and CFP-
10, and up to 80% of humans and nonhuman primates show
reactogenicity to both of them [83–86]. Moreover, these
human T cell epitopes were shown to be evolutionary con-
served in the related members of the MTBC [48]. Andrews
et al., showed that individuals with latent TB infection (LTBI)
had up to 79% lower risk of progressive TB disease after
reinfection than uninfected individuals [47], powerfully denot-
ing that vaccines that replicate this level of risk reduction
would likewise be important in controlling TB. These studies
support the idea that the immune response in LTBI, and there-
fore, selection of immunodominant antigens could be of sig-
nificant benefit to achieve protection against TB disease [83].
Taken together, these observations call for more in-depth
characterization of the ability of MTBVAC to induce immune
reactivity to the immunodominant antigens ESAT-6 and CFP-
10 in humans. Moreover, it would be important to investigate
whether preexisting immune sensitization to BCG, NTM, and
or M. tuberculosis in adolescents and adults, which could result
in potential masking and blocking effects to vaccination,
would affect MTBVAC-induced immunity in presensitized indi-
viduals relative to the naïve immune system of newborns. And
ultimately, deciphering whether MTBVAC-induced specific
immunity to ESAT-6, CFP-10 and or other immune-dominant
M. tuberculosis antigens could play a role in improved TB
protection in humans may help in the identification of reliable
antigen-specific correlates of protection. Elaborate preclinical
efficacy studies in macaque models may be a highly valuable
opportunity for such studies because of the ability of this
species to recognize the majority of the experimentally iden-
tified human T cell antigens [83,84].
9. Expert commentary
Priming immunity with live vaccines is considered to induce
specific long-lasting memory immune responses, which is not
observed with subunit vaccines, and this effect could be related
to restricted persistence or replication in vivo as observed for
other human live vaccines (e.g. polio, measles, yellow fever) [38].
Although debatable in clinic, live BCG is typically the most pro-
tective vaccine against M. tuberculosis in experimental animal
models [38], which makes one consider that human vaccination
with live-attenuated M. tuberculosis (e.g. MTBVAC) would induce
specific long-term immune responses against certain T cell epi-
topes that are present in M. tuberculosis and absent in BCG and
which may be important for protection [38,83]. Moreover, neo-
natal vaccination with live-attenuated M. tuberculosis vaccines
could represent by far the most effective strategy for conferring
high-quality protective immunity against TB, as healthy new-
borns represent the most sensitive and immunologically naïve
population without preexisting mycobacterial immunity, which
in older age groups can lead to potential masking and blocking
effects to vaccination [18,87]. Additionally, considering the simi-
lar biological nature of novel live-attenuated M. tuberculosis
vaccines and BCG makes one consider that these novel candi-
dates may also possess the inherent nonspecific benefits attrib-
uted to BCG and as such, it would be important to consider
evaluating them in advanced clinical development trials.
Despite inherent risks with preexisting mycobacterial sensi-
tization, in 2014, the BMGF revised its TB vaccine strategy
shifting entirely supporting discovery and development of
novel preventive TB vaccines in adolescents and adults,
where the greatest impact on TB transmission is expected to
be observed [88]. This important shift, which was possibly
driven by the unsuccessful outcome of MVA85A phase IIb
infant efficacy trial [15], has left infant TB prevention strategies
with little to no priority in the current BMGF TB vaccine
agenda [34]. Moreover, a strong emphasis on the need for
diversifying the vaccine concepts in the clinical pipeline was
also placed by the revised TB vaccine strategy, as the majority
of candidates are subunit approaches of which six of the eight
subunits contain an Ag85 antigen (either Ag85A or Ag85B),
most designed to provoke cell-mediated immunity driven by
CD4 and CD8 T cells, resulting in vaccines with little immuno-
logic diversity [34]. Driven by this new shift in agenda, in July
2015 BMGF launched the Collaboration for TB Vaccine
Discovery (CTVD), which comprises an international network
of selected scientists and experts dedicated to innovation and
collaboration in basic discovery, preclinical development, and
early phase I and smaller experimental medicine trials of new
TB vaccines [89]. Likewise, the new TB vaccine strategy has
influenced vaccine developers of new live mycobacterial
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vaccines, like MTBVAC, to consider expanding the target popu-
lation to encompass M. tuberculosis unexposed and exposed
adolescents and adults.
The revised BMGF TB vaccine strategy has also set new
gating decisions for clinical evaluation of new TB vaccines,
which are based on NHP models and small experimental
clinical trials in humans with two outcomes: immune signa-
tures, that is, detailed immune responses measured, and pro-
tection following challenge with TB [89]. A product
representing a distinct concept/hypothesis that vows promise
in these studies will be selected for clinical development [89].
However, there are important limitations with the current NHP
models requiring consideration, especially if efficacy in differ-
ent animal models that could include macaques will be used
by BMGF to decide on the fate of a candidate. For example, in
the current animal models, including macaques, BCG is con-
sidered to work so well that it leaves little room for improve-
ment for new candidates implying the need for large group
numbers to achieve statistical significance in improved effi-
cacy, which could make such studies practically and ethically
unfeasible, and prohibitively expensive. Moreover, depending
on the macaque species, different disease outcomes may be
observed that could affect interpretation of study results.
Cynomolgus macaques are known to be prone to developing
latent infection, so that about 50 % of non-vaccinated controls
in a study will not show clinical signs of active disease [90],
which may have some resemblance to TB outcome in humans,
but it makes data analysis difficult. Rhesus macaques on the
other hand are considered more sensitive to TB infection and
disease; however, this model calls for or a design that includes
larger number of animals per group to achieve statistical
significance when comparing new vaccine candidates to
BCG, thus highly increasing cost of experiment. Nowadays
PET CT scanning is used to evaluate pathology in lungs, and
this method is considered more reliable than CFU measure
[91]. Despite these important limitations to the nonhuman
primate models, a promising ultra-low-dose aerosol challenge
(<20 CFU) model in nonhuman primates has been established
at the PHE and can use survival end points, as reported for
another candidate in the pipeline [92].
Finally, if animal models including nonhuman primate
models are to be employed in the decision-making process
for selecting a candidate to advance to community-wide effi-
cacy trials, considerations for incorporating elements of the
planned clinical program (e.g. phase II dose-defining study)
are necessary to allow closer comparability of nonhuman
primate and clinical data. These elements include target age
(e.g. adolescents or young adults), previous mycobacterial
sensitization (e.g. to BCG vaccination at birth), exact clinical
route, and regimen of vaccination, and the clinical immunolo-
gical assays used or planned for use for vaccine characteriza-
tion and dose definition. For example, the whole-blood
intracellular staining (WB-ICS) assay, originally developed by
Prof. Willem Hanekom (former SATVI director, current deputy
director TB vaccines at BMGF) is now widely used as one of the
standard immunological characterization tests in TB vaccine
clinical trials, as in the phase Ia of MTBVAC [70] or in other
trials at SATVI [37,93–96]. Moreover, considerations for inves-
tigating ESAT-6 and CFP-10 conversion kinetics and how they
can relate to vaccine induced protection will be made. Also,
other possibilities for reliable differentiation between MTBVAC
vaccination and M. tuberculosis infection should also be
investigated.
10. Five-year view
Altogether, the next five years are filled with many challenges
and anticipations for MTBVAC, as well as for other vaccines in
the TB vaccine development community. Being the only live
M. tuberculosis vaccine in the pipeline of clinical development
and considering the inherent rich antigen-specific repertoire
which is differential to that of BCG, MTBVAC represents the
most unique opportunity to study and understand what is
needed in terms of an effective immunity against M. tubercu-
losis infection and disease establishment. Immunological data
from the planned dose-defining MTBVAC clinical trials in new-
borns and adolescents will allow establishing qualitative and
quantitative differences between MTBVAC- and BCG-triggered
responses. Moreover, parallel protection experiments in NHP,
faithfully mirroring the planned immunological tests in phase
IIa will permit comparison of immunological and protective
efficacy data in the quest to identify reliable correlates of
protection for use in community-wide phase IIb efficacy trials.
In this context, collaborations on a global level with wide
range of expertise in the field of TB and vaccine development
would be enthusiastically embraced.
Key issues
● MTBVAC is the first live attenuated M. tuberculosis-based
vaccine to enter clinical development, a historic milestone
in human vaccinology.
● MTBVAC has shown improved or comparable safety and
efficacy to BCG in relevant preclinical animal models.
● The first Phase 1a trial with MTBVAC showed that the
vaccine is as at least as safe as BCG SSI.
● MTBVAC is currently being evaluated in a Phase 1b trial in
newborns, South Africa.
● MTBVAC Clinical Development Plans target TB prevention in
newborns, as a BCG replacement strategy, and in adoles-
cents and adults.
● According to the new TB vaccine strategy of the major
funder BMGF, in addition to demonstrated safety and
immunogenicity in early human clinical trials, convincing
NHP efficacy and experimental medicine studies, are
needed to support progress to community-wide Phase 2b
efficacy evaluation.
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